BOULDER, Colo., Apr 23, 2012 (BUSINESS WIRE) --Array BioPharma Inc. (Nasdaq:ARRY) will report financial results for the
third quarter of fiscal 2012 on Monday, April 30, 2012, and will hold a
conference call on Tuesday, May 1, 2012 at 9:00 a.m. Eastern time to
discuss these results. Michael Carruthers, Chief Financial Officer, and
Kevin Koch, Ph.D., President and Chief Scientific Officer, will lead the
A replay of the call will be available as a webcast on www.arraybiopharma.com
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small-molecule
drugs to treat patients afflicted with cancer and inflammatory diseases.
Array has four core proprietary clinical programs: ARRY-614 for
myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for
pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded
clinical programs including two MEK inhibitors in Phase 2: selumetinib
with AstraZeneca and MEK162 with Novartis. For more information on
Array, please go to www.arraybiopharma.com.
SOURCE: Array BioPharma Inc.
Array BioPharma Inc.
Tricia Haugeto, 303-386-1193